Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.
about
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferretsMaking better influenza virus vaccines?H5N1 vaccines in humansTargeted vaccine selection in influenza vaccinationSingle-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 virusesIdentification of critical residues in the hemagglutinin and neuraminidase of influenza virus H1N1pdm for vaccine virus replication in embryonated chicken eggsImmunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primatesImparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60.Control of influenza virus infection by immunity to conserved viral features.Vaccines for pandemic influenzaNew vaccines against influenza virus.Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccinesA live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.Adenoviral vectors as novel vaccines for influenza.A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferretsInfluenza vaccines: from surveillance through production to protection.Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic VirusCold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice.Novel vaccines against influenza viruses.The receptor binding specificity of the live attenuated influenza H2 and H6 vaccine viruses contributes to vaccine immunogenicity and protection in ferrets.Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses.Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.Immunobiology of influenza vaccinesA step closer to meeting the threat of avian influenza.Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferretsMultiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66.Molecular basis of live-attenuated influenza virus.Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus.Emerging respiratory viruses: challenges and vaccine strategiesInfluenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals.Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsAttenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cellsEvaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.
P2860
Q21563426-427566AA-109D-4AF3-96B4-CF402E2E339FQ22305647-89CA06EC-D77B-4DB7-BA5B-C9DDE86D22A8Q27000896-6FAD3817-2FC1-466F-92FF-82FA01304FBEQ27030899-D6515687-C25A-4B53-90CD-BBE92ED0C917Q27318575-BC12420D-2986-4AC0-91AD-A1A2DF6FC100Q28396825-89689299-0D82-405E-9EA4-DF793ED0D3E0Q28475369-7FDFA27A-2736-43F5-BCA8-8BB073F38366Q30336518-095AC804-69A1-45E6-B650-F67CB0088167Q30343902-C4D79FCD-9DC2-422E-B270-431C3653AED6Q30353073-9E3805FA-F586-473F-B3E6-0CC27C146C8EQ30357932-82E8CBD1-0680-484A-AFF8-A9C02CD18D85Q30362811-DEEE3E41-E430-4219-BE9F-A0FDCDFDE47BQ30365696-BC47C758-207A-4B68-B2E7-40D16F420057Q30370303-06AF8B03-C59F-48FD-B6E4-C0B3E61126FEQ30370445-46B4E8A1-B304-4E80-B0E5-62BED7675E90Q30374887-5C590BF7-88AF-4F85-A988-0DF1176DEAF7Q30377205-DC05A49A-469F-449C-9D4D-FB6D5ADF1EDFQ30383905-59C6FD97-F542-43FE-9E45-67060C3FD91EQ30385118-67301C57-34B5-4B54-BE7A-003FBA7D4980Q30390811-67703950-9611-48D7-9AD5-95DF0EC3CBF2Q30405211-81196348-FE5E-44DF-A5EB-9FB36B646CEBQ30407716-24D53F13-0059-494D-BC1B-D71BFBDC9265Q30410954-CC35CE79-0990-4538-8114-143C7B4BFC67Q30414665-310068C5-9CA8-422D-A8F2-1512EDDA53E4Q30420603-579138FE-C107-4327-AC9C-620093A9DAA4Q30426771-AACB2897-99FE-4394-9D60-86C47C39A572Q33257256-DE1306DD-1D53-4027-A115-A0124897A030Q33743763-8B1EBCF0-8968-4713-9880-3782A3657A73Q34560137-B8E80FAE-AEAD-47E4-9F85-DE17C90AE3DCQ34653879-9FFC7048-8683-4D10-AD7D-9EC3065C46F6Q34820655-9461D889-3385-47E2-B9F4-E94712036917Q34991413-6F4FEFEA-661C-4E63-B27D-321A0E484333Q35018600-24AF92ED-1002-404C-BBC8-D9B3AB49548AQ35070868-3E21D063-F7AE-455C-8AAD-2D04868FECF5Q35629114-444575CE-8F90-4936-8D74-8DFE4BE18765Q35710438-F502A211-B7C0-4494-B899-5F6BD5C08665Q35826747-ED4849D2-225F-4AD3-82A0-C05040CC365AQ35924915-C995D59E-4028-414C-B0C7-AE54BE2F6C0FQ35991598-33F2A658-91A6-442D-A197-3BB428B42972Q36017724-614182C2-97D2-4BB7-B2A8-0A550428852C
P2860
Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Principles underlying the deve ...... luenza A and B virus vaccines.
@ast
Principles underlying the deve ...... luenza A and B virus vaccines.
@en
Principles underlying the deve ...... luenza A and B virus vaccines.
@nl
type
label
Principles underlying the deve ...... luenza A and B virus vaccines.
@ast
Principles underlying the deve ...... luenza A and B virus vaccines.
@en
Principles underlying the deve ...... luenza A and B virus vaccines.
@nl
prefLabel
Principles underlying the deve ...... luenza A and B virus vaccines.
@ast
Principles underlying the deve ...... luenza A and B virus vaccines.
@en
Principles underlying the deve ...... luenza A and B virus vaccines.
@nl
P1433
P1476
Principles underlying the deve ...... luenza A and B virus vaccines.
@en
P2093
Brian R Murphy
Kathleen Coelingh
P304
P356
10.1089/08828240260066242
P577
2002-01-01T00:00:00Z